HIV Integrase
HIV integrase is one of the three key enzymes of the pol gene of HIV. HIV integrase catalyzes the insertion into the genome of the infected human cell of viral DNA produced by the retrotranscription process. This unique step in the virus life cycle provides a variety of points for intervention and hence is an attractive target for the development of new therapeutics for the treatment of AIDS. HIV integrase includes HIV-1 and HIV-2 integrases.
HIV-1 integrase is a 32-kDa enzyme that carries out DNA integration in a two-step reaction. In the first step, called 3′ processing, two nucleotides are removed from each 3′ end of the viral DNA made by reverse transcription. In the next step, called DNA strand transfer, a pair of transesterification reactions integrates the ends of the viral DNA into the host genome. Integrase is comprised of three structurally and functionally distinct domains, and all three domains are required for each step of the integration reaction.
All Product Categories
-
HIV Integrase Related Products (107)
Related Products (107)
-
LEDGIN6
0 ImagesSynonyms: CX05168; CX04328LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of LEDGF/p75 and HIV integrase.
-
Ethyl salvianolate A
0 ImagesCat. No.: HY-N16050CAS No.: 1015171-68-2Synonyms: Ethyl salvionolate AEthyl salvianolate A (Ethyl salvionolate A) is an anti-HIV-1 compound that can be extracted from the roots of Salvia yunnanensis. Ethyl salvianolate A inhibits P24 antigen in HIV-1 infected MT-4 cell cultures (EC50: 1.44 μg/mL). Ethyl salvianolate A inhibits HIV-1 replicative enzymes, with IC50s of 56.38 μM (Reverse transcriptase), 12.03 μM (Protease), 14.54 μM (Integrase), respectively.
-
BDM-2
0 ImagesBDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC50=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC50 value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC50 value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity.
-
Bis-T-23
0 ImagesCat. No.: HY-123572CAS No.: 171674-76-3Synonyms: AG1717
-
GSK-364735
0 ImagesCat. No.: HY-16907CAS No.: 863434-13-3Synonyms: S/GSK-364735
-
HIV-1 integrase inhibitor 4
0 ImagesCat. No.: HY-108820CAS No.: 1638504-66-1
-
HIV-1 integrase inhibitor 3
0 ImagesCat. No.: HY-108817CAS No.: 1638504-56-9
-
MK-2048
0 ImagesCat. No.: HY-13305CAS No.: 869901-69-9MK-2048 is a HIV-1 and HIV-1 integrase inhibitor. MK-2048 shows selective activity against HTLV-1-infected cells and retained potency against HIV-1 variants. MK-2048 induces apoptosis, inhibits cell growth, reduces proviral loads, and blocks HTLV-1 transmission and immortalization. MK-2048 can be used for the research of HIV-1 infection.
-
Cabotegravir-d5
0 ImagesSynonyms: GSK-1265744-d5; S/GSK1265744-d5Cabotegravir-d5 is deuterium labeled Cabotegravir.
-
HIV-1 integrase inhibitor
0 ImagesCat. No.: HY-13025CAS No.: 544467-07-4HIV-1 integrase inhibitor is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
-
Bictegravir sodium (Standard)
0 ImagesSynonyms: GS-9883 sodium (Standard)Bictegravir (sodium) (Standard) is the analytical standard of Bictegravir (sodium). This product is intended for research and analytical applications. Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity.
-
Elvitegravir (Standard)
0 ImagesSynonyms: GS-9137 (Standard); JTK-303 (Standard); D06677 (Standard)Elvitegravir (Standard) is the analytical standard of Elvitegravir. This product is intended for research and analytical applications. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.
-
4-epi-Dolutegravir
0 ImagesCat. No.: HY-W781966CAS No.: 1357289-37-24-epi-Dolutegravir (compound H3) is the (4S, 12aS) diastereomer of Dolutegravir (HY-13238), and also a hydrolytic degradation product of a HIV integrase inhibitor.
-
Dolutegravir (Standard)
0 ImagesSynonyms: S/GSK1349572 (Standard)Dolutegravir (Standard) is the analytical standard of Dolutegravir. This product is intended for research and analytical applications. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).
-
Raltegravir sodium
0 ImagesCat. No.: HY-10353BCAS No.: 1292804-07-9Synonyms: MK 0518 sodiumRaltegravir (MK 0518) sodium is a potent and orally active integrase (IN) inhibitor, used to treat HIV infection.
